

RESEARCH

Open Access



The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trial

Philipp Heinrich Baldia¹, Bernhard Wernly², Hans Flaatten³, Jesper Fjølner⁴, Antonio Artigas⁵, Bernardo Bollen Pinto⁶, Joerg C. Schefold⁷, Malte Kelm¹, Michael Beil⁸, Raphael Romano Bruno¹, Stephan Binnebößel¹, Georg Wolff¹, Ralf Erkens¹, Sviril Sigal⁸, Peter Vernon van Heerden⁸, Wojciech Szczeklik⁹, Muhammed Elhadi¹⁰, Michael Joannidis¹¹, Sandra Oeyen¹², Brian Marsh¹³, Finn H. Andersen¹⁴, Rui Moreno¹⁵, Susannah Leaver¹⁶, Dylan W. De Lange¹⁷, Bertrand Guidet¹⁸, Christian Jung^{1*} and COVIP study group

Abstract

Background: In the early COVID-19 pandemic concerns about the correct choice of analgesics in patients with COVID-19 were raised. Little data was available on potential usefulness or harmfulness of prescription free analgesics, such as paracetamol. This international multicentre study addresses that lack of evidence regarding the usefulness or potential harm of paracetamol intake prior to ICU admission in a setting of COVID-19 disease within a large, prospectively enrolled cohort of critically ill and frail intensive care unit (ICU) patients.

Methods: This prospective international observation study (The COVIP study) recruited ICU patients ≥ 70 years admitted with COVID-19. Data on Sequential Organ Failure Assessment (SOFA) score, prior paracetamol intake within 10 days before admission, ICU therapy, limitations of care and survival during the ICU stay, at 30 days, and 3 months. Paracetamol intake was analysed for associations with ICU-, 30-day- and 3-month-mortality using Kaplan Meier analysis. Furthermore, sensitivity analyses were used to stratify 30-day-mortality in subgroups for patient-specific characteristics using logistic regression.

Results: 44% of the 2,646 patients with data recorded regarding paracetamol intake within 10 days prior to ICU admission took paracetamol. There was no difference in age between patients with and without paracetamol intake. Patients taking paracetamol suffered from more co-morbidities, namely diabetes mellitus (43% versus 34%, $p < 0.001$), arterial hypertension (70% versus 65%, $p = 0.006$) and had a higher score on Clinical Frailty Scale (CFS; IQR 2–5 versus IQR 2–4, $p < 0.001$). Patients under prior paracetamol treatment were less often subjected to intubation and vasopressor use, compared to patients without paracetamol intake (65 versus 71%, $p < 0.001$; 63 versus 69%, $p = 0.007$). Paracetamol intake was not associated with ICU-, 30-day- and 3-month-mortality, remaining true after multivariate adjusted analysis.

*Correspondence: christian.jung@med.uni-duesseldorf.de

¹ Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusion: Paracetamol intake prior to ICU admission was not associated with short-term and 3-month mortality in old, critically ill intensive care patients suffering from COVID-19.

Trial registration.

This prospective international multicentre study was registered on ClinicalTrials.gov with the identifier “NCT04321265” on March 25, 2020.

Keywords: COVID-19, Frailty, ICU, Paracetamol, Analgesics

Background

Older patients are more likely to die from COVID-19, the disease caused by Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) [1]. Early studies of COVID-19 have shown that especially old and frail patients are at particular risk for a worse outcome compared to younger people, with case fatality rates increasing up to 14.8% in patients aged 80 years and more. The majority of COVID-19 related deaths are in patients aged 80 years or greater [1–5]. These observations are in line with past studies of outcome of frail intensive care unit (ICU) patients showing that frailty – and not old age alone—is an important predictor of outcome in critically ill patients [6, 7]. In response to the eminently high vulnerability of old and frail patients, many countries chose to prioritize this vulnerable group in their vaccination programs to protect them from a likely fatal outcome [8]. This patient cohort is also of particular interest since they frequently take inter-current medications and have comorbid conditions.

In the early phase of the COVID-19 pandemic there were warnings not to use prescription-free analgesics such as ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs), since they were suspected to cause higher morbidity and mortality. Those statements were taken up by the media and led to widespread confusion and fear of – up to then – commonly used drugs for everyday ailments, like headaches and fever [9, 10].

Several studies suggested a potential influence of NSAIDs on the clinical course of respiratory viral diseases, namely worsening the overall outcome due to a suppression of the initial inflammatory cascade [11, 12]. Despite an early focus on a potential detrimental effect of NSAIDs on clinical outcomes, studies have shown no association of NSAID use with mortality [12, 13]. However, the role and influence of paracetamol, often used as an alternative to NSAIDs, remains unclear. To date, no data are available on the effects of paracetamol intake on COVID-19 disease in the vulnerable cohort of very old and critically ill patients admitted to ICUs.

This international multicentre study addresses this lack of evidence regarding the usefulness or potential harm of paracetamol intake prior to ICU admission in a setting of

COVID-19 disease within a large, prospectively enrolled cohort of critically ill and frail ICU patients.

Methods

Design and settings

This international multicentre study is part of the Very old Intensive care Patients (VIP) project and has been endorsed by the European Society of Intensive Care Medicine (ESICM, <http://www.vipstudy.org>). Furthermore, it was registered on ClinicalTrials.gov (ID: NCT04321265) and planned in adherence to the European Union General Data Privacy Regulation (GDPR) directive, which is implemented in most participating countries. The COVIP (COVID-19 in very old intensive care patients) investigation aims to improve and enhance the knowledge about relevant factors for predicting mortality in older COVID-19 patients to help detect these patients early on and prevent a worse outcome. National coordinators were responsible for ICU recruitment, coordination of national and local ethical permissions and supervision of patient recruitment, as in the previous VIP studies [14, 15]. Ethical approval was mandatory for study participation. In most of the countries informed consent was obligatory for inclusion. However, due to a waiver of informed consent by some local Ethics committees, in a few countries, recruitment was possible without informed consent as previously described [16]. Overall, 138 intensive care units from 28 countries participated in the COVIP study [5, 17]. A list of all collaborating centers is given in the acknowledgement section.

Study population

COVIP recruited patients with proven COVID-19, defined as a positive polymerase chain reaction (PCR) test result, aged 70 years or older who were admitted to an ICU. Data collection started at ICU admission. Thus, data about pre-ICU triage were not available. The admission day was defined as day one, and all consecutive days were numbered sequentially from the admission date. The dataset contained patients enlisted to the COVIP study from 19th March 2020 until the 4th of February 2021.

Data collection

All study sites used a uniform online electronic case report form (eCRF). For this subgroup analysis, only patients with documented information regarding intake of paracetamol up to ten days prior to ICU admission were included.

Paracetamol intake

Paracetamol intake was defined as any oral or intravenous intake regardless of dosage and duration within the ten days prior to ICU admission, including during prior hospitalization, as reported by patient interviews; in case the patient was not able to respond, the relatives were asked to provide information. No differentiation was made between regular or irregular, i.e., single use, in reporting paracetamol intake.

The Sequential Organ Failure Score (SOFA) on admission was recorded [14, 15]. For calculation of the Horowitz Index (p_aO_2/FiO_2 -ratio), the first arterial blood gas analysis after ICU admission was used ideally within one hour of ICU admission. Additionally, the need for non-invasive (NIV) or invasive ventilation, prone positioning, tracheostomy, vasopressor use, renal replacement therapy (RRT) and limitation or withdrawal of life-sustaining therapy during the ICU stay were recorded.

Data storage

The eCRF was constructed with the REDCap software [18]. Data storage and hosting of the eCRF took place on a secure server of Aarhus University in Denmark. The servers were operated in collaboration between the Information Technology Department and the Department of Clinical Medicine of the Aarhus University.

Frailty assessment

The frailty level prior to the acute illness and hospital admission was assessed using the Clinical Frailty Scale (CFS) as described previously [14, 15]. Patients were grouped into three categories: fit (CFS 0–3) vulnerable (CFS 4) and frail (CFS ≥ 5).

Statistical analysis

Continuous data were described as median \pm interquartile range (IQR). Differences between independent groups were calculated using the Mann Whitney U-test. Categorical data were expressed as percentages. Kaplan–Meier analysis was used for assessment of mortality. For calculating differences between groups, the chi-square test was applied. Univariate and multivariate logistic regression analyses were performed to assess associations of paracetamol use with ICU-,

30-days and 3-months-mortality. We report (adjusted) odds ratios (OR) with respective 95% confidence intervals (CI). We performed sensitivity analyses plotting univariate OR and 95%CI. All tests were two-sided. A p-value of <0.05 was considered statistically significant. Stata 16 was used for all statistical analyses (StataCorp LLC, 4905 Lakeway Drive, College Station, Brownsville, Texas, USA).

Results

Demographic data (age, sex, frailty, co-morbidities)

The study included 2,646 patients in total, of which 1,480 patients (56%) did not take paracetamol up to ten days prior to admission to an intensive care unit, whereas 1,166 patients (44%) confirmed paracetamol intake prior to ICU admission. The median age was 75 years in both groups (IQR 72–79 years, $p>0.98$); significantly more women reported an intake of paracetamol 10 days prior to ICU admission. Patients on paracetamol intake were slightly more frail in comparison to patients without paracetamol intake (IQR 2–5 versus 2–4, $p<0.001$). In addition, patients using paracetamol had more co-morbidities, such as arterial hypertension and diabetes mellitus in comparison to non-users (43% versus 34%, $p<0.001$ for diabetes mellitus and 70% vs 65%, $p=0.006$ for arterial hypertension). Concerning the occurrence of COVID-19 symptoms, patients under treatment with paracetamol had a shorter duration from symptom onset until ICU admission in comparison with patients without paracetamol medication (6 versus 7 days, $p=0.01$). Additional data regarding patient demographics and co-morbidities are displayed in Table 1.

Treatment in intensive care units

We observed a significant difference in SOFA scores on ICU admission between the two groups: those who received paracetamol treatment were admitted with a slightly higher SOFA score compared to those without paracetamol intake (5 versus 5, IQR 3–8 versus 3–8; cf. Table 1; $p=0.004$). Furthermore, we observed several differences in intensive care treatment: Patients on paracetamol treatment prior to ICU admission were significantly less often subjected to endotracheal intubation and vasopressor treatment (65% versus 71%, $p<0.001$ and 63% versus 68%, $p=0.007$, respectively). No difference in tracheostomy rates were observed (16% versus 19%, $p=0.073$). Additionally, the need for renal replacement therapy and NIV did not differ between both groups (14% versus 15%, $p=0.3$; 26% vs 27%, $p=0.58$, respectively). Concerning treatment withholding and withdrawal, patients with a reported paracetamol intake were less likely to be subjected to either treatment withholding or withdrawal, such as discontinuing respiratory

Table 1 Patient characteristics

	No paracetamol intake (n = 1480)	paracetamol intake (n = 1166)	p-value
Male sex (n)	73% (1076)	65% (753)	<0.001
Age in years	75 (72–79)	75 (72–79)	0.98
70–79 years (n)	80% (1178)	78% (908)	
80–89 years (n)	19% (286)	21% (248)	
> 90 years (n)	1% (16)	1% (10)	
BMI	27 (25–31)	28 (25–31)	0.93
SOFA Score	5 (3–8)	5 (3–8)	0.004
CFS	3 (2–4)	3 (2–5)	<0.001
Comorbidities			
Diabetes mellitus	34% (495)	43% (495)	<0.001
Arterial hypertension	65% (957)	70% (814)	0.006
CAD	24% (350)	25% (286)	0.61
Chronic heart failure	14% (210)	15% (177)	0.47
Pulmonary disease	23% (333)	22% (258)	0.91
CKD	16% (235)	18% (213)	0.097

Abbreviations: BMI Body mass index (kg/m²), CAD Coronary artery disease, CFS Clinical Frailty Scale, CKD Chronic kidney disease, IQR Interquartile range, SD Standard deviation, SOFA Sequential Organ Failure Assessment

Categorical variables displayed as % (n), continuous variables as median (IQR). Patients with reported paracetamol intake had a higher SOFA Score on ICU admission than those without paracetamol intake

or circulatory support, when compared to those without paracetamol intake (25% versus 29%, $p = 0.021$; 16% versus 19%, $p = 0.011$, respectively).

Mortality

No difference in mortality was observed between patients with and without paracetamol intake up to ten days prior to ICU admission (Fig. 1): ICU mortality was 46% vs 48% ($p = 0.3$) in patients with and without paracetamol intake respectively; 30-day mortality was 48% versus 51% ($p = 0.12$) in patients with and without paracetamol intake; 3-month mortality rates were 60% versus 64% ($p = 0.059$), respectively.

Sensitivity analyses stratifying 30-day-mortality into subgroups for patient-specific characteristics using logistic regression producing univariate odds ratios are shown in Fig. 2. The 30-day-mortality was similar between patients with and without paracetamol intake regardless of treatment limitations, the use of NIV, age strata and the time from symptom onset until admission. There was a trend towards higher mortality in patients with paracetamol intake without intubation and in vulnerable patients as assessed by CFS.

After adjustment for age, sex, SOFA score and CFS at admission, paracetamol use was not associated with ICU (aOR 0.93 95%CI 0.78–1.11; $p = 0.42$), 30-day (aOR 0.86 95%CI 0.72–1.03; $p = 0.10$) and 3-month (aOR 0.88 95%CI 0.72–1.07; $p = 0.20$) mortality.

Discussion

In this subgroup analysis of critically ill patients ≥ 70 years of age, we investigated the influence of prior paracetamol intake on short-term and long-term mortality in patients with COVID-19. At the beginning of the pandemic, on the 14th of March




Fig. 1 Kaplan–Meier curve for patients with (red) and without (blue) paracetamol intake prior to up to ten days before admission to intensive care units for COVID-19 (with 95% confidence interval)




Fig. 2 Sensitivity analyses stratifying 30-day-mortality in subgroups for patient-specific characteristics using logistic regression producing univariate odds ratios. The 30-day-mortality was similar between patients with and without paracetamol intake regardless of treatment limitations, the use of NIV, age strata and the time from symptom onset until admission. Patients categorized as vulnerable according to CFS (OR 0.36) and without endotracheal intubation and vasopressor use (OR 0.62, respectively) were more likely to take paracetamol

2020, the French Ministry of Health published data on 400 patients suffering from a severe clinical course of COVID-19 after taking ibuprofen; it therefore advised against the use of ibuprofen and other NSAIDs as the analgesics and antipyretics of choice. Instead, several health experts advised the use of paracetamol in case of fever or pain [9, 19, 20]. Previous studies investigated possible pathophysiological mechanisms by which NSAIDs and paracetamol could influence the clinical course of an infection with SARS-CoV-2 and other respiratory viruses [12, 21–23].

Paracetamol on the other hand is not included in the group of NSAIDs and has a more pronounced effect on cyclooxygenase (COX) 3 iso-enzyme, which is located in the central nervous system in contrast to the COX variants 1 and 2; thus, paracetamol has more central antipyretic and analgesic effects without compromising the systemic inflammatory cascade [24, 25]. Our findings are in line with current literature, confirming the safety of paracetamol as a potent analgesic and antipyretic drug in viral infections and especially in the case of COVID-19 disease [26, 27]. This is even true in a setting of critically

ill and vulnerable, very old and frail people admitted to an ICU. We found no association of paracetamol intake prior to ICU admission with either ICU-, 30-day- and 3-months-mortality in patients with COVID-19 aged 70 years or more.

Since the study at hand did not report on analgesic use other than paracetamol, e.g., aspirin or NSAIDs, it remains unclear, whether paracetamol has any specific impact on the clinical course concerning the extent of intensive care treatment. Additionally, no differences in renal replacement therapy were observed. This may be explained by the mainly hepatic metabolism of paracetamol and a central activation of the COX 1 splice variant COX 3 as stated above [11, 24, 25, 28].

Patients on paracetamol treatment prior to hospitalization were also less prone to treatment withholding or withdrawal in comparison with those without paracetamol intake. In the light of the increased frailty of the paracetamol group, it remains unclear, why, despite this difference in co-morbidities, such as arterial hypertension and diabetes, they were less likely to have treatment withheld and withdrawn. This may be the result of the heterogeneity due to the international and multicentric setup of the COVIP study; hence individual differences, ethical, socio-medical patient backgrounds and the current epidemiological local burden of COVID-19 disease in the study sites must be considered, when discussing the observed differences in therapy and therapeutic limitations.

Our results are in line with findings by Park and colleagues, who showed safety of paracetamol in comparison to ibuprofen regarding the outcome of COVID-19 disease by analysing a propensity matched cohort of Korean patients in the first wave of the SARS-CoV-2 pandemic [29]. Similar results were published by Rinott et al. in a retrospective study on Israeli patients with a median age of 45 years, who reported ibuprofen or paracetamol intake up to 14 days prior to study inclusion; no difference in mortality or respiratory support rates were observed [30]. Further data on safety of paracetamol and NSAIDs were provided by Chandan and colleagues in a retrospective propensity matched study of 17,190 patients with osteoarthritis in the United Kingdom, who were prescribed either paracetamol and codeine, paracetamol and dihydrocodeine or NSAID: the study showed no increased risk of COVID-19 disease or mortality in both groups [31].

Importantly, we do neither observe paracetamols efficacy nor its safety in use. In summary, our multi-centre study suggests safety of paracetamol intake prior to hospitalization in intensive care units in a vulnerable and frail collective of more than 70 years old patients suffering from COVID-19 disease. This hypothesis is

based on the evidence provided within this international, prospective multicentre study.

Limitations

Our study has some methodological limitations. Firstly, the study lacks a control group of younger patients admitted to ICU wards for severe COVID-19. Secondly, no control group of non-ICU patients age ≥ 70 was analyzed. Furthermore, data recording was only limited to time after ICU admission, thus leaving out information on pre-ICU care and possible triage. In addition, no detailed information on ICU equipment, quality of care, nurse-patient ratios and measure of staff stress was obtained; neither was paracetamol use during ICU treatment addressed. These local circumstances may affect the care of older ICU patients [32]. Also, participating countries varied widely in their care structure, thus resulting in a large heterogeneity in the level of care and the regional burden of care regarding local COVID-19 cases. Regarding paracetamol intake, we did not assess and document the doses of paracetamol ingested. Limitations of care in the pandemic surges did not allow to measure plasma metabolites and estimate true drug exposure, thus limiting data reliability. Lastly, our study did not analyze the intake of non-steroidal anti-inflammatory drugs, such as ibuprofen or aspirin and their corresponding impact on mortality and clinical course. Therefore, no recommendation towards a specific subgroup of analgesics can be made.

Conclusion

In the international multicentre COVIP study of old, critically ill patients with COVID-19, we found no association of paracetamol intake prior to ICU admission with short-term and 3-month mortality. Paracetamol is therefore likely safe for analgesic and antipyretic use in this group.

Abbreviations

BMI: Body mass index (kg/m^2); CAD: Coronary artery disease; CFS: Clinical Frailty Scale; CI: Confidence interval; CKD: Chronic kidney disease; COVID-19: Coronavirus disease 2019; COX: Cyclooxygenase; eCRF: Electronic case report form; FiO_2 : Fraction of inspired oxygen; ICU: Intensive care unit; IQR: Interquartile range; NIV: Non-invasive ventilation; NSAID: Non-steroidal anti-inflammatory drug; (a)OR: (Adjusted) odds ratio; p_aO_2 : Arterial partial oxygen pressure; RRT: Renal replacement therapy; SARS-CoV-2: Severe acute respiratory syndrome coronavirus type 2; SD: Standard deviation; SOFA: Sequential Organ Failure Score.

Acknowledgements

List of collaborators of the COVIP-study group.

Hospital	City	ICU	Name	Region-shospitalet	Randers	Intensiv	Helle Bundgaard
Austria							
Medical University Graz	Graz	Allgemeine Medizin Intensivstation	Philipp Eller	Aarhus University Hospital	Aarhus	Department of Intensive Care	Jesper Fjølner
Medical University Innsbruck	Innsbruck	Division of Intensive Care and Emergency Medicine, Department of Internal Medicine	Michael Joannidis	England			
				Musgrove Park	Adult ICU	Taunton	Richard Innes
				Princess Alexandra Hospital Harlow	Princess Alexandra Hospital ICU	Essex	James Gooch
				Royal Papworth Hospital	Cardiothoracic Critical Care	Cambridge	Lenka Cagova
				Royal Surrey Hospital NHS Foundation Trust	Intensive Care Unit	Guildford	Elizabeth Potter
				Russells Hall	Russells Hall Anaes Dept	Dudley	Michael Reay
				Tunbridge Wells Hospital	Tunbridge Wells Intensive Care/High Dependency Unit	Tunbridge Wells	Miriam Davey
				Walsall Manor Hospital	Walsall ICU	Walsall	Mohammed Abdelshafy Abusayed
				West Suffolk NHS Foundation Trust	Critical Care	Bury St Edmunds	Sally Humphreys
Belgium				France			
Ziekenhuis Oost-Limburg	Genk	Department of Intensive Care	Dieter Mesotten	Hôpital Privé Claude Galien	Quincy sous Sénart	Medico-surgical ICU	Arnaud Galbois
CHR Haute Senne	Soignies	Department of Intensive Care	Pascal Reper	Saint Antoine	Paris	Medical ICU	Bertrand Guidet
Ghent University Hospital	Ghent	Department of Intensive Care	Sandra Oeyen	Hôpital Ambroise Paré	Boulogne Billancourt	Medico-surgical ICU	Cyril Charron
AZ Sint-Blasius	Dendermonde	Department of Intensive Care	Walter Swinnen	Hopital Européen Georges Pompidou	Paris	Medical ICU	Caroline Hauw Berlemont
Clinique Saint Pierre Ottignies	Ottignies	Department of Intensive Care	Nicolas Serck	CHU de Besançon	Besançon	Medico-surgical ICU	Guillaume Besch
Universitair Ziekenhuis Brussel	Brussel	ICU UZB	ELISABETH DEWAELE	Dieppe General Hospital	Dieppe	Medical ICU	Jean-Philippe Rigaud
Denmark				CHU Amiens Tenon	Amiens Paris	Medical ICU	Julien Maizel Michel Djibré
Herlev og Gentofte Hospital	Herlev	Intensiv Behandling	Helene Brix	Clinique Du Millenaire	Montpellier	Surgical ICU	Philippe Burtin
Slagelse Region-shospitalet Horsens	Slagelse Horsens	Intensiv Intensiv	Jens Brushoej Pritpal Kumar	Marne La Vallee	Jossigny	Medico-surgical ICU	Pierre Garcon
Odense University Hospital	Odense	Intensive Care Unit	Helene Korvenius Nedergaard	CHU Lille	Lille	Medical ICU	Saad Nseir
Sygehus Lillebælt	Kolding	Intensiv	Helene Korvenius Nedergaard	CHU de Caen	Caen	Medical ICU	Xavier Valette
Regionshospitalet Viborg	Viborg	Intensiv	Ida Riise Balleby	Compiègne Noyon Hospital	Compiègne	Medico-surgical ICU	Nica Alexandru
Sygehus Sønderjylland	Aabenraa Sønderjylland	Department of Anaesthesia and Intensive Care	Camilla Bundesen	Cochin	Paris	Medical ICU	Nathalie Marin
Regionshospitalet Herning	Herning	Intensiv Afdeling	Maria Aagaard Hansen	CH Pau	Pau	Medico-surgical ICU	Marie Vaissiere
Nordsjællands Hospital	Hillerød	Department of Anaesthesia and Intensive Care	Stine Uhrenholt				

Victor Dupouy	Argenteuil	Medico-surgical ICU	Gaëtan PLANTEFEVE	Uniklinik Schleswig Holstein Campus Kiel	Kiel	Internistische Intensivstation	Matthias Lutz
CH Saint Philibert	Lomme lez Lille	Medical ICU	Thierry Vanderlinden	Johanna Etienne Krankenhaus	Neuss	Station 2	Gonxhe Shala
Beaujon	Clichy	Medico-surgical ICU	Igor Jurcisin	Kliniken Maria Hilf	Mönchengladbach	Internistische Intensivstation I und II	Hendrik Haake
Lariboisière	Paris	Medical ICU	Buno Megarbane	Krankenhaus Bethanien GmbH Solingen	Solingen	Intensivpflege Bethanien	Winfried Randerath
Lariboisière	Paris	Surgical ICU	Benjamin Glenn Chousterman	Uniklinik Düsseldorf	Düsseldorf	MX01	Anselm Kunstein
Saint-Louis	Paris	Surgical ICU	François Dépret	University Hospital Würzburg	Würzburg		Patrick Meybohm
Saint Antoine	Paris	Surgical ICU	Marc Garnier	Charité - Universitätsmedizin Berlin	Berlin	43i	Stefan Schaller
Louis Mourier	Colombes	Medico-surgical ICU	Sebastien Besset	St Vincenz	Limburg	ICU	Stephan Steiner
Avicenne	Bobigny	Medico-surgical ICU	Johanna Oziel	University Hospital Ulm	Ulm	IOI-Interdisziplinäre Operative Intensivmedizin	Eberhard Barth
Centre hospitalier de Versailles	Le Chesnay	Medico-surgical ICU	Alexis Ferre	Marienhospital Aachen	Aachen	ITS	Tudor Poerner
Robert Debré	Paris	Pediatric ICU	Stéphane Dauger	University Hospital Leipzig / Klinik und Poliklinik für Anästhesiologie und Intensivtherapie	Leipzig	IOI (Interdisciplinary Operational/ Surgical ICU)	Philipp Simon
Saint-Louis	Paris	Medical ICU	Guillaume Dumas	Charité - Universitätsmedizin Berlin	Berlin	203i	Marco Lorenz
Sainte-Anne	Paris	Medico-surgical ICU	Bruno Goncalves	Städtische Kliniken Mönchengladbach	Mönchengladbach	Interdisziplinäre Intensivstation	Zouhir Dindane
CHU de Besancon	Besançon	Medical ICU	Lucie Vettoretti	Charité - Universitätsmedizin Berlin	Berlin	144i	Karl Friedrich Kuhn
CH Dr SCHAFFNER, Reanimation polyvalente	Lens	Medico-surgical ICU	Didier Thevenin	Klinikum Darmstadt GmbH	Darmstadt	Interdisziplinäre Operative Intensivstation Klinik fuer Anaesthesiologie und operative Intensivmedizin	Martin Welte
Germany							
Charité - Universitätsmedizin Berlin	Berlin	44i	Stefan Schaller				
Charité - Universitätsmedizin Berlin	Berlin	W1	Stefan Schaller				
Florence-Nightingale Krankenhaus	Duesseldorf	32	Muhammed Kurt				
Kliniken Nordoberpfalz AG Klinikum Weiden	Weiden	Interdisziplinäre Intensivmedizin	Andreas Faltthäuser				
Charité - Universitätsmedizin Berlin	Berlin	8i	Stefan Schaller				
Evangelisches Krankenhaus Düsseldorf	Düsseldorf	Intensivstation	Christian Meyer				
Malteser Krankenhaus St. Franziskus Hospital	Flensburg	Intensivstation 1	Milena Milovanovic				

Elisabeth-Krankenhaus Essen	Essen	Kardiologisch-internistische Intensivstation	Ingo Voigt	Netherland				
Klinikum Konstanz	Konstanz	I01	Hans-Joachim Kabitz	Alrijne Zorggroep	Leiderdorp	ICU Department	Martijn Groenendijk	
Medical Center - University of Freiburg	Freiburg	Anaesthesiologische Intensivtherapiestation	Jakob Wollborn	Canisius Wilhelmina Hospital	Nijmegen	C38	Mirjam Evers	
St. Franziskus-Hospital Münster	Münster	Klinik für Anästhesie und operative Intensivmedizin	Ulrich Goebel	Canisius Wilhelmina Ziekenhuis	Nijmegen	ICU Department	Mirjam Evers	
University Hospital Cologne	Cologne	Surgical ICU of the Department of Anesthesiology	Sandra Emily Stoll	Diakonessenhuis Utrecht	Utrecht	Diakonessenhuis	Lenneke van Lelyveld-Haas	
University Hospital Duesseldorf	Duesseldorf	CIA1	Detlef Kindgen-Milles	Haga Ziekenhuis	The Hague	ICU Haga	Iwan Meynaar	
Essen University Hospital	Essen	Ana Int	Simon Dubler	Medisch Spectrum Twente	Enschede	Intensive Care Center	Alexander Daniel Cornet	
University Hospital Duesseldorf	Düsseldorf	M11/2	Christian Jung	Radboudumc	Nijmegen	Intensive Care department Radboudumc	Marieke Zegers	
Rechts der Isar Technical University	Munich	ICU 1	Kristina Fuest	University Medical Center Groningen	Groningen	Department of Critical Care	Willem Dieperink	
Universitätsmedizin der Johannes Gutenberg-Universität Mainz	Mainz	Anästhesie-Intensivstation	Michael Schuster	University Medical Center Utrecht	Utrecht	Intensive Care	Dylan de Lange	
Greece				Zuyderland mc	Heerlen	Intensive Care	Tom Dormans	
GENERAL HOSPITAL OF LARISSA	LARISSA	ICU	Antonios Papadogoulas	Norway				
General University Hospital of Patras	Patras	MEΘ	Francesk Mulita	Haugesund Hospital	Haugesund	ICU	Michael Hahn	
Sotiria Hospital National and Kapodistrian University of Athens	Athens	ICU 1st Pulmonary and Critical Care Medicine Dpt	Nikoletta Rovina	Haukeland University Hospital	Bergen	KSK-ICU	Britt Sjøbøe	
Ught Ahepa UNIVERSITY HOSPITAL (ATTIKON)	Thessaloniki	Metha	Zoi Aidoni	Kristiansund Hospital Helse Møre og Romsdal HF	Kristiansund	ICU	Hans Frank Strietzel	
UNIVERSITY HOSPITAL OF HERAKLION	HERAKLION	ICU UNIVERSITY HOSPITAL OF HERAKLION	EUMORFIA KONDILI	Oslo University Hospital	Oslo	Surgical ICU	Theresa Olasveengen	
UNIVERSITY HOSPITAL OF IOANNINA	IOANNINA	INTENSIVE CARE UNIT	Ioannis Andrianopoulos	Oslo University Hospital Rikshospitalet Medical	Oslo	Department of Critical Care and Emergencies	Luis Romundstad	
				Ålesund Hospital	Ålesund	Dept. Anesthesia and Intensive Care Surgical ICU	Finn H. Andersen	
				Poland				
				Clinical Hospital Heliodor Świącicki Medical University of Karol Marcinkowski in Poznan	Poznan	Anesthesiology Intensive Therapy and Pain Treatment	Anna Kluzik	

Infant Jesus Clinical Hospital Medical University of Warsaw	Warsaw	I Department of Anaesthesiology and Intensive Care	Paweł Zatorski	Spain				
Jagiellonia University Hospital Cracow	Cracow		Tomasz Drygalski	Clínico Universitario Lozano-Blesa	Zaragoza	Unidad de Cuidados Intensivos	M José Arche Banzo	
Military Hospital	Krakow	ICU	Wojciech Szczeklik	Clínico Universitario Lozano-Blesa	Zaragoza	Unidad de Cuidados Intensivos	Begoña Zalba-Etayo	
Military Institute of Medicine	Warsaw	COVID-19 ICU	Jakub Klimkiewicz	COMPLEJO ASISTENCIAL DE SEGOVIA	SEGOVIA	UCI SEGOVIA	PATRICIA JIMENO CUBERO	
Pomeranian Medical University	szczecin	ICU	Joanna Solek-pastuszka	Complexo Hospitalario Universitario Ourense	Ourense	UCI CHUO	Jesús Priego	
Provincial Specialist Hospital	Olsztyn	Department of Intensive Care	Dariusz Onichimowski	Corporació Sanitària Parc Taulí	Sabadell	Parc Taulí	Gemma Gomà	
SPSK-1	Lublin	II Klinika Anestezjologii i Intensywnej Terapii	Mirosław Czuczwar	Germans Trias i Pujol	Badalona	General ICU	Teresa Maria Tomasa-Irriguible	
University Hospital in Opole	Opole	Department of Anaesthesiology and Intensive Care	Ryszard Gawda	H. Universitari i Politècnic La Fe	Valencia	General ICU	Susana Sancho	
Uniwersyteckie Centrum Kliniczne w Gdańsku	Gdańsk	Klinika Anestezjologii i Intensywnej Terapii	Jan Stefaniak	Hospital Alvaro Cunqueiro	Vigo	Servicio de Medicina Intensiva CHUVI	Aida Fernández Ferreira	
Voivodship Hospital in Poznan	Poznan	Intensive Care Unit	Karina Stefanska-Wronka	Hospital de Tortosa Verge de la Cinta	Tortosa	Unidad de Cuidados Intensivos	Eric Mayor Vázquez	
ZDROWIE Sp. z o.o.	Kwidzyn	Oddział Anestezjologii i Intensywnej Terapii	Ewa Zabul	Hospital General Universitario de Albacete	Albacete	aapm111	Ángela Prado Mira	
Portugal				Hospital Universitario Sagrat Cor	Barcelona	ICU	Mercedes Ibarz	
Centro Hospitalar de Tondela-Viseu EPE	Viseu	Unidade de Cuidados Intensivos Polivalente	Ana Isabel Pinho Oliveira	Hospital Universitario de Burgos	Burgos	UCI Burgos	David Iglesias	
Centro Hospitalar do Médio Tejo	Abrantes	Serviço de Medicina Intensiva	Rui Assis	Hospital Universitario de Getafe	Getafe	Medical-Surgical ICU	Fernando Frutos-Vivar	
Centro Hospitalar e Universitário São João	Porto	Infectious Diseases ICU	Maria de Lurdes Campos Santos	Hospital universitario Rey Juan Carlos	Mostoles	Cuidados intensivos	Sonia Lopez-Cuenca	
Centro Hospitalar Trás os Montes e Alto Dour	Vila Real	D	Henrique Santos	Hospital Universitario Rio Hortega	Valladolid	Reanimación Quirúrgica	Cesar Aldecoa	
Curry Cabral Hospital	Lisbon	UCIP	Filipe Sousa Cardoso	Hospital Universitario Rio Hortega	Valladolid	Servicio de Medicina Intensiva - Unidad 1	David Perez-Torres	
Hospital de Beatriz Ângelo	Loures	Serviço de Medicina Intensiva	André Gordinho	Hospital Universitario Rio Hortega	Valladolid	Servicio de Medicina Intensiva - Unidad 2	Isabel Canas-Perez	
				Hospital Universitario Rio Hortega	Valladolid	Servicio de Medicina Intensiva - Unidad 3	Luis Tamayo-Lomas	

Hospital Universitario Río Hortega	Valladolid	Servicio de Medicina Intensiva - Unidad 4	Cristina Diaz-Rodriguez
Miguel Servet University Hospital	Zaragoza	Servicio de Medicina Intensiva	Pablo Ruiz de Gopegui
Switzerland			
Centre Hospitalier Universitaire Vaudois	Lausanne	Service de Médecine Intensive Adulte (SMIA)	Nawfel Ben-Hamouda
Clinica Luganese Moncucco	Lugano	Servizio di anestesia e rianimazione	Andrea Roberti
Fribourg Hospital	Fribourg	Intensive Care Unit	Yvan Fleury
Geneva University Hospitals	Geneva	Department of Acute Medicine	Nour Abidi
Inselspital Bern	Bern	Universitätsklinik für Intensivmedizin	Joerg C. Schefold
Kantonsspital Thurgau Frauenfeld	Frauenfeld	Institut für Anästhesiologie und Intensivmedizin	Ivan Chau
Kantonsspital Thurgau Frauenfeld	Frauenfeld	Institut für Anästhesiologie und Intensivmedizin	Alexander Dullenkopf
Wales			
Glan Clwyd Hospital	Bodelwyddan	Critical Care Unit	Richard Pugh
Wrexham Maelor Hospital	Wrexham	Critical Care	Sara Smuts

Authors' contributions

PHB, BW and CJ analyzed the data and wrote the first draft of the manuscript. HF and BG and DL contributed to statistical analysis and improved the paper. MK and MB and RRB and SB and GW and RE and SS and PVH and ME and MJ and AA and BG and FHA and SL and JF and BM and RM and SO and BP and WS and JCS gave guidance and improved the paper. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. This study was endorsed by the European Society of Intensive Care Medicine (ESICM). Free support for running the electronic database and was granted from the Department of Epidemiology, University of Aarhus, Denmark. The support of the study in France by a grant from Fondation Assistance Publique-Hôpitaux de Paris pour la recherche is greatly appreciated. In Norway, the study was supported by a grant from the Health Region West. In addition, the study was supported by a grant from the European Open Science Cloud (EOSC). EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant agreement number [831644]. This work was supported by the Forschungskommission of the Medical Faculty of the Heinrich-Heine-University Düsseldorf, No. [2018-32] to GW and No. [2020-21] to RRB for a Clinician Scientist Track. No (industry) sponsorship has been received for this investigator-initiated study.

Availability of data and materials

Individual participant data that underlie the results reported in this article are available to investigators whose proposed use of the data has been approved by the COVIP steering committee. The anonymized data used and analyzed in this study can be requested from the corresponding author on reasonable request if required.

Declarations

Ethics approval and consent to participate

The primary competent ethics committee was the Ethics Committee of the University of Duesseldorf, Germany (application number 2020-892). Each participating center received a copy of the study protocol. Institutional research ethic board approval was obtained from each study site and was mandatory for study participation.

Due to the observational nature of the study, participation in this study did not impact medical procedures, which were all executed in accordance with the relevant medical guidelines and regulations. No additional examinations, e.g., sampling and storage of biomaterials, such as blood or CT-scans and X-rays, were performed.

The study was planned in adherence to the European Union General Data Privacy Regulation (GDPR) directive, which is implemented in most participating countries. Deceased patients were included within strict consideration of local requirements set up by the local ethics committees. However, in a few countries, recruitment was possible without informed consent in accordance with the respective local ethics committee (see above).

Consent for publication

The manuscript does not contain any individual person's data in any form.

Competing interests

The authors declare that they have no competing interests. JCS reports grants (full departmental disclosure) from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Philips Medical, Phagenesis Ltd, Prolong Pharmaceuticals and Nycomed outside the submitted work. The money went into departmental funds. No personal financial gain applied.

Author details

¹Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. ²Department of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria. ³Department of Clinical Medicine, Department of Anaesthesia and Intensive Care, University of Bergen, Haukeland University Hospital, Bergen, Norway. ⁴Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark. ⁵Critical Care Centre, Sabadell Hospital University Institute Parc Tauli, Sabadell Barcelona, Spain. ⁶Department of Acute Medicine, Geneva University Hospitals, Geneva, Switzerland. ⁷Department of Intensive Care Medicine, Inselspital, Universitätsspital, University of Bern, Bern, Switzerland. ⁸General & Medical Intensive Care Units, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. ⁹Department of Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland. ¹⁰Faculty of Medicine, University of Tripoli, Tripoli, Libya. ¹¹Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria. ¹²Department of Intensive Care 1K12IC, Ghent University Hospital, Ghent, Belgium. ¹³Mater Misericordiae University Hospital, Dublin, Ireland. ¹⁴Department Of Anaesthesia and Intensive Care, Ålesund Hospital, Ålesund, Norway. Dep. of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. ¹⁵Multipurpose and Neurocritical Intensive Care Unit, Hospital of São José, Central Lisbon University Hospital Centre, Lisbon, Portugal. ¹⁶General Intensive Care, St George'S University Hospitals NHS Foundation Trust, London, UK. ¹⁷Department of Intensive Care Medicine, University Medical Center, University Utrecht,

Utrecht, Netherlands. ¹⁸Institute Pierre Louis Epidemiology and Public Health, Medical Intensive Care Unit, Sorbonne University, UPMC, INSERM, Hôpital Saint-Antoine, Paris, France.

Received: 14 January 2022 Accepted: 19 December 2022
Published online: 27 December 2022

References

- Smorenberg A, Peters EJ, van Daele P, Nossent EJ, Muller M. How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. *Eur J Intern Med*. 2021;83:1–5.
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239–42.
- Nachtigall I, Lenga P, Jozwiak K, Thurmann P, Meier-Hellmann A, Kuhlen R, Brederlau J, Bauer T, Tebbenjohanns J, Schwegmann K, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. *Clin Microbiol Infect*. 2020;26(12):1663–9.
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430–6.
- Jung C, Flaatten H, Fjølner J, Bruno RR, Wernly B, Artigas A, Bollen Pinto B, Scheffold JC, Wolff G, Kelm M, et al. The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study. *Crit Care*. 2021;25(1):149.
- Muscenedere J, Waters B, Varambally A, Bagshaw SM, Boyd JG, Maslove D, Sibley S, Rockwood K. The impact of frailty on intensive care unit outcomes: a systematic review and meta-analysis. *Intensive Care Med*. 2017;43(8):1105–22.
- Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, Pearce L, Stechman M, Short R, Price A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. *Lancet Public Health*. 2020;5(8):e444–51.
- Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, Larremore DB. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science*. 2021;371(6532):916–21.
- Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. *BMJ*. 2020;368: m1086.
- Anti-inflammatoires non stéroïdiens (AINS) et complications infectieuses graves [https://ansm.sante.fr/actualites/anti-inflammatoires-non-steroïdiens-ains-et-complications-infectieuses-graves#_ftn1]
- Micallef J, Soeiro T, Jonville-Bera AP. French Society of Pharmacology T: Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. *Therapie*. 2020;75(4):355–62.
- Robb CT, Goepf M, Rossi AG, Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. *Br J Pharmacol*. 2020;177(21):4899–920.
- Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, Hardwick HE, Docherty AB, Thwaites RS, Openshaw PJM, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. *Lancet Rheumatol*. 2021;3(7):e498–506.
- Flaatten H, De Lange DW, Morandi A, Andersen FH, Artigas A, Bertolini G, Boumendil A, Cecconi M, Christensen S, Faraldi L, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (>= 80 years). *Intensive Care Med*. 2017;43(12):1820–8.
- Guidet B, de Lange DW, Boumendil A, Leaver S, Watson X, Boulanger C, Szczeklik W, Artigas A, Morandi A, Andersen F, et al. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study. *Intensive Care Med*. 2020;46(1):57–69.
- Bruno RR, Wernly B, Kelm M, Boumendil A, Morandi A, Andersen FH, Artigas A, Finazzi S, Cecconi M, Christensen S, et al. Management and outcomes in critically ill nonagenarian versus octogenarian patients. *BMC Geriatr*. 2021;21(1):576.
- Jung C, Bruno RR, Wernly B, Joannidis M, Oeyen S, Zafeiridis T, Marsh B, Andersen FH, Moreno R, Fernandes AM, et al. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients. *Eur Heart J Cardiovasc Pharmacother*. 2021;7(1):76–7.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377–81.
- Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. *Circulation*. 2009;119(18):2471–9.
- Little P. Non-steroidal anti-inflammatory drugs and covid-19. *BMJ*. 2020;368: m1185.
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271–80 e278.
- Cabbab ILN, Manalo RVM. Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection. *Virus Res*. 2021;291: 198190.
- Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired Pneumonia in Adult and Pediatric Patients. *J Clin Med*. 2019;8(6):786.
- Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci U S A*. 2002;99(21):13926–31.
- Sharma CV, Mehta V. Paracetamol: mechanisms and updates. *Contin Educ Anaesth Crit Care Pain*. 2014;14(4):153–8.
- von Philipsborn P, Biallas R, Burns J, Drees S, Geffert K, Movsisyan A, Pfadenhauer LM, Sell K, Strahwald B, Stratil JM, et al. Adverse effects of non-steroidal anti-inflammatory drugs in patients with viral respiratory infections: rapid systematic review. *BMJ Open*. 2020;10(11): e040990.
- Crighton AJ, McCann CT, Todd EJ, Brown AJ. Safe use of paracetamol and high-dose NSAID analgesia in dentistry during the COVID-19 pandemic. *Br Dent J*. 2020;229(1):15–8.
- Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. *J Gastroenterol Hepatol*. 2014;29(7):1356–60.
- Park J, Lee SH, You SC, Kim J, Yang K. Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19. *Sci Rep*. 2021;11(1):5087.
- Rinott E, Kozar E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. *Clin Microbiol Infect*. 2020;26(9):1259–e5.
- Chandan JS, Zemedikun DT, Thayakaran R, Byrne N, Dhalla S, Acosta-Mena D, Gokhale KM, Thomas T, Sainsbury C, Subramanian A, et al. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. *Arthritis Rheumatol*. 2021;73(5):731–9.
- Flaatten H, deLange D, Jung C, Beil M, Guidet B. The impact of end-of-life care on ICU outcome. *Intensive Care Med*. 2021;47(5):624–5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.